{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:46:05Z","timestamp":1770507965786,"version":"3.49.0"},"reference-count":232,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2014,7,28]],"date-time":"2014-07-28T00:00:00Z","timestamp":1406505600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0103345","type":"journal-article","created":{"date-parts":[[2014,7,28]],"date-time":"2014-07-28T18:10:22Z","timestamp":1406571022000},"page":"e103345","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":189,"title":["Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention"],"prefix":"10.1371","volume":"9","author":[{"given":"Lucas","family":"Wiessing","sequence":"first","affiliation":[]},{"given":"Marica","family":"Ferri","sequence":"additional","affiliation":[]},{"given":"Bart","family":"Grady","sequence":"additional","affiliation":[]},{"given":"Maria","family":"Kantzanou","sequence":"additional","affiliation":[]},{"given":"Ida","family":"Sperle","sequence":"additional","affiliation":[]},{"given":"Katelyn J.","family":"Cullen","sequence":"additional","affiliation":[]},{"name":"EMCDDA DRID group","sequence":"additional","affiliation":[]},{"given":"Angelos","family":"Hatzakis","sequence":"additional","affiliation":[]},{"given":"Maria","family":"Prins","sequence":"additional","affiliation":[]},{"given":"Peter","family":"Vickerman","sequence":"additional","affiliation":[]},{"given":"Jeffrey V.","family":"Lazarus","sequence":"additional","affiliation":[]},{"given":"Vivian D.","family":"Hope","sequence":"additional","affiliation":[]},{"given":"Catharina","family":"Mathe\u00ef","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2014,7,28]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, et al. (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798\u2013801. nature08463 [pii]; 10.1038\/nature08463 [doi].","DOI":"10.1038\/nature08463"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1469-0691.2010.03432.x","article-title":"Evolving epidemiology of hepatitis C virus","volume":"17","author":"D Lavanchy","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1055\/s-0031-1297923","article-title":"HCV routes of transmission: what goes around comes around","volume":"31","author":"MJ Alter","year":"2011","journal-title":"Semin Liver Dis"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Wiessing L, Guarita B, Giraudon I, Brummer-Korvenkontio H, Salminen M, et al. (2008) European monitoring of notifications of hepatitis C virus infection in the general population and among injecting drug users (IDUs) - the need to improve quality and comparability. Euro Surveill 13: pii = 18884. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.eurosurveillance.org\/ViewArticle.aspx?ArticleId=18884\" xlink:type=\"simple\">http:\/\/www.eurosurveillance.org\/ViewArticle.aspx?ArticleId=18884<\/ext-link>.","DOI":"10.2807\/ese.13.21.18884-en"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jama.285.8.1003","article-title":"Former addicts face barriers to treatment for HCV","volume":"285","author":"J Stephenson","year":"2001","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"King LA, Le SY, Meffre C, Delarocque-Astagneau E, Desenclos JC (2009) Assessment and proposal of a new combination of screening criteria for hepatitis C in France. Eur J Public Health 19: 527\u2013533. ckp112 [pii]; 10.1093\/eurpub\/ckp112 [doi].","DOI":"10.1093\/eurpub\/ckp112"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5: 558\u2013567. S1473-3099(05)70216-4 [pii]; 10.1016\/S1473-3099(05)70216-4 [doi].","DOI":"10.1016\/S1473-3099(05)70216-4"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F (2013) The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 58: 593\u2013608. S0168-8278(12)00924-5 [pii]; 10.1016\/j.jhep.2012.12.005 [doi].","DOI":"10.1016\/j.jhep.2012.12.005"},{"key":"ref9","first-page":"321","article-title":"Treatment of chronic hepatitis C: current and future","volume":"369","author":"JM Pawlotsky","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1086\/600304","article-title":"Hepatitis C treatment for injection drug users: a review of the available evidence","volume":"49","author":"M Hellard","year":"2009","journal-title":"Clin Infect Dis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"S210","DOI":"10.1002\/hep.1840360727","article-title":"Prevention and Treatment of Hepatitis C in Injection Drug Users","volume":"36","author":"BR Edlin","year":"2002","journal-title":"Hepatology"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Dalgard O (2005) Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin Infect Dis 40 Suppl 5: S336\u2013S338. CID34655 [pii]; 10.1086\/427449 [doi].","DOI":"10.1086\/427449"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/jvh.12008","article-title":"Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers","volume":"19","author":"P Bruggmann","year":"2012","journal-title":"J Viral Hepat"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1097\/QAD.0b013e32801086da","article-title":"Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic","volume":"20","author":"SH Mehta","year":"2006","journal-title":"AIDS"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s10900-007-9083-3","article-title":"Limited uptake of hepatitis C treatment among injection drug users","volume":"33","author":"SH Mehta","year":"2008","journal-title":"J Community Health"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Grebely J, Raffa JD, Lai C, Krajden M, Kerr T, et al. (2009) Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 16: 352\u2013358. JVH1080 [pii]; 10.1111\/j.1365-2893.2009.01080.x [doi].","DOI":"10.1111\/j.1365-2893.2009.01080.x"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, et al. (2013) Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 57 Suppl 2: S80\u2013S89. cit306 [pii]; 10.1093\/cid\/cit306 [doi].","DOI":"10.1093\/cid\/cit306"},{"key":"ref18","unstructured":"NCHECR (2003) HIV\/AIDS, viral hepatitis and sexually transmissible infections in Australia. Annual Surveillance Report 2003. Sydney: National Centre in HIV Epidemiology and Clinical Research (NCHECR), The University of New South Wales."},{"key":"ref19","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/jvh.12129","article-title":"Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999\u20132011","volume":"21","author":"J Iversen","year":"2014","journal-title":"J Viral Hepat"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Strathdee SA, Latka M, Campbell J, O\u2019Driscoll PT, Golub ET, et al. (2005) Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis 40 Suppl 5: S304\u2013S312. CID34650 [pii]; 10.1086\/427445 [doi].","DOI":"10.1086\/427445"},{"key":"ref21","first-page":"296A","article-title":"Low uptake of treatment for hepatitis C virus (HCV) infection in a large community-based cohort of illicit drug users in Vancouver","volume":"46","author":"J Grebely","year":"2007","journal-title":"Hepatology"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1017\/S0950268804003486","article-title":"Management of chronic hepatitis C in French departments of internal medicine and infectious diseases","volume":"133","author":"P Cacoub","year":"2005","journal-title":"Epidemiol Infect"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1360-0443.2011.03638.x","article-title":"Psychiatric comorbidity and the persistence of drug use disorders in the United States","volume":"107","author":"MC Fenton","year":"2012","journal-title":"Addiction"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.20882\/adicciones.91","article-title":"Psychiatric morbidity among cocaine and heroin users in the community","volume":"24","author":"S Tortajada","year":"2012","journal-title":"Adicciones"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"6703","DOI":"10.3748\/wjg.v19.i40.6703","article-title":"Hepatitis C, stigma and cure","volume":"19","author":"RT Marinho","year":"2013","journal-title":"World J Gastroenterol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1478-3231.2011.02706.x","article-title":"Barriers to hepatitis C treatment","volume":"32","author":"CE McGowan","year":"2012","journal-title":"Liver Int"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7517-11-1","article-title":"Barriers and facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study","volume":"11","author":"JA Barocas","year":"2014","journal-title":"Harm Reduct J"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/hep.24656","article-title":"Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations","volume":"55","author":"NK Martin","year":"2012","journal-title":"Hepatology"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jhep.2010.08.029","article-title":"Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility","volume":"54","author":"NK Martin","year":"2011","journal-title":"J Hepatol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/hep.26431","article-title":"Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals","volume":"58","author":"NK Martin","year":"2013","journal-title":"Hepatology"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Zeiler I, Langlands T, Murray JM, Ritter A (2010) Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs. Drug Alcohol Depend 110: 228\u2013233. S0376-8716(10)00106-7 [pii]; 10.1016\/j.drugalcdep.2010.03.006 [doi].","DOI":"10.1016\/j.drugalcdep.2010.03.006"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/09687630802227673","article-title":"From margin to mainstream: the evolution of harm reduction responses to problem drug use in Europe","volume":"15","author":"D Hedrich","year":"2008","journal-title":"Drugs Educ Prev Policy"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2105\/AJPH.2008.141846","article-title":"Associations between availability and coverage of HIV-prevention measures and subsequent incidence of diagnosed HIV infection among injection drug users","volume":"99","author":"L Wiessing","year":"2009","journal-title":"Am J Public Health"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Lettmeier B, Muhlberger N, Schwarzer R, Sroczynski G, Wright D, et al. (2008) Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol 49: 528\u2013536. S0168-8278(08)00351-6 [pii]; 10.1016\/j.jhep.2008.04.021 [doi].","DOI":"10.1016\/j.jhep.2008.04.021"},{"key":"ref35","unstructured":"WHO (2014) Guidelines for the Screening, Care and Treatment of Persons with Hepatitis Infection. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/apps.who.int\/iris\/bitstream\/10665\/111747\/1\/9789241548755_eng.pdf?ua=1&ua=1\" xlink:type=\"simple\">http:\/\/apps.who.int\/iris\/bitstream\/10665\/111747\/1\/9789241548755_eng.pdf?ua=1&amp;ua=1<\/ext-link>."},{"key":"ref36","unstructured":"Pawlotsky JM, Aghemo A, Dusheiko G, Forns X, Puoti M, et al. (2014) EASL Recommendations on Treatment of Hepatitis C - 2014."},{"key":"ref37","doi-asserted-by":"crossref","first-page":"S373","DOI":"10.1086\/427456","article-title":"Guidelines for the treatment of hepatitis C virus infection in injection drug users: status quo in the European Union countries","volume":"40","author":"J Reimer","year":"2005","journal-title":"Clin Infect Dis"},{"key":"ref38","unstructured":"Wiessing L (2001) The access of injecting drug users to hepatitis C treatment is low and should be improved. Euro Surveill 5: pii = 1709. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.eurosurveillance.org\/ViewArticle.aspx?ArticleId=1709\" xlink:type=\"simple\">http:\/\/www.eurosurveillance.org\/ViewArticle.aspx?ArticleId=1709<\/ext-link>."},{"key":"ref39","unstructured":"The Scottish Government (2008) Hepatitis C Action Plan for Scotland, Phase II: May 2008 \u2013 March 2011. Edinburgh: The Scottish Government."},{"key":"ref40","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/gut.42.6.892","article-title":"French consensus conference on hepatitis C: screening and treatment","volume":"42","author":"JP Galmiche","year":"1998","journal-title":"Gut"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Lindenburg CEA, Lambers FAE, Urbanus AT, Schinkel J, Jansen PLM, et al. (2011) Hepatitis C testing and treatment among active drug users in Amsterdam: Results from the DUTCH-C project. European Journal of Gastroenterology and Hepatology 23: January. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/dx.doi.org\/10.1097\/MEG.0b013e328340c451\" xlink:type=\"simple\">http:\/\/dx.doi.org\/10.1097\/MEG.0b013e328340c451<\/ext-link>.","DOI":"10.1097\/MEG.0b013e328340c451"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3109\/10826084.2013.793356","article-title":"Hepatitis C among injecting drug users is two times higher in Stockholm, Sweden than in Rotterdam, the Netherlands","volume":"48","author":"L Norden","year":"2013","journal-title":"Subst Use Misuse"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, et al. (2011) Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378: 571\u2013583. S0140-6736(11)61097-0 [pii]; 10.1016\/S0140-6736(11)61097-0 [doi].","DOI":"10.1016\/S0140-6736(11)61097-0"},{"key":"ref44","unstructured":"Wiessing L, Likatavicius G, Hedrich D, Guarita B, van de Laar MJ, et al. (2011) Trends in HIV and hepatitis C virus infections among injecting drug users in Europe, 2005 to 2010. Euro Surveill 16: pii = 20031. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.eurosurveillance.org\/ViewArticle.aspx?ArticleId=20031\" xlink:type=\"simple\">http:\/\/www.eurosurveillance.org\/ViewArticle.aspx?ArticleId=20031<\/ext-link>."},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Hahne SJ, Veldhuijzen IK, Wiessing L, Lim TA, Salminen M, et al. (2013) Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis 13: 181. 1471-2334-13-181 [pii]; 10.1186\/1471-2334-13-181 [doi].","DOI":"10.1186\/1471-2334-13-181"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/jmv.23370","article-title":"Hepatitis C virus infection among drug addicts in Italy","volume":"84","author":"T Stroffolini","year":"2012","journal-title":"J Med Virol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1086\/321909","article-title":"Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis","volume":"33","author":"CS Graham","year":"2001","journal-title":"Clin Infect Dis"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Rantala M, van de Laar MJ (2008) Surveillance and epidemiology of hepatitis B and C in Europe - a review. Euro Surveill 13.","DOI":"10.2807\/ese.13.21.18880-en"},{"key":"ref49","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2014) European Drug Report 2014. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.emcdda.europa.eu\/edr2014\" xlink:type=\"simple\">http:\/\/www.emcdda.europa.eu\/edr2014<\/ext-link>."},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"John-Baptiste A, Yeung MW, Leung V, van der Velde G, Krahn M (2012) Cost effectiveness of hepatitis C-related interventions targeting substance users and other high-risk groups: a systematic review. Pharmacoeconomics 30: 1015\u20131034. 1 [pii]; 10.2165\/11597660-000000000-00000 [doi].","DOI":"10.2165\/11597660-000000000-00000"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1055\/s-0031-1297922","article-title":"What is killing people with hepatitis C virus infection","volume":"31","author":"J Grebely","year":"2011","journal-title":"Semin Liver Dis"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"114","DOI":"10.7326\/0003-4819-158-2-201301150-00576","article-title":"Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review","volume":"158","author":"R Chou","year":"2013","journal-title":"Ann Intern Med"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1473-3099(12)70010-5","article-title":"Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine","volume":"12","author":"J Grebely","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"ref54","first-page":"41","article-title":"Management of chronic hepatitis in drug addicts: a systematic review","volume":"159","author":"AM Pellicelli","year":"2008","journal-title":"Clin Ter"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1258\/RSMSMJ.51.2.8","article-title":"Hepatitis C virus infection in Scotland: epidemiological review and public health challenges","volume":"51","author":"SJ Hutchinson","year":"2006","journal-title":"Scott Med J"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2893.2006.00812.x","article-title":"High incidence of hepatitis C virus reinfection within a cohort of injecting drug users","volume":"14","author":"JM Micallef","year":"2007","journal-title":"J Viral Hepat"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jclinepi.2011.12.012","article-title":"Decisions about lumping vs. splitting of the scope of systematic reviews of complex interventions are not well justified: a case study in systematic reviews of health care professional reminders","volume":"65","author":"MC Weir","year":"2012","journal-title":"J Clin Epidemiol"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62: e1\u201334. S0895-4356(09)00180-2 [pii]; 10.1016\/j.jclinepi.2009.06.006 [doi].","DOI":"10.1016\/j.jclinepi.2009.06.006"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Ebner N, Wanner C, Winklbaur B, Matzenauer C, Jachmann CA, et al. (2009) Retention rate and side effects in a prospective trial on hepatitis C treatment with pegylated interferon alpha-2a and ribavirin in opioid-dependent patients. Addict Biol 14: 227\u2013237. ADB148 [pii]; 10.1111\/j.1369-1600.2009.00148.x [doi].","DOI":"10.1111\/j.1369-1600.2009.00148.x"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group","volume":"339","author":"JG McHutchison","year":"1998","journal-title":"N Engl J Med"},{"key":"ref61","first-page":"19","article-title":"Vyskyt virovych hepatitid typu B a C ve skupine injekcnich uzivatelu drog v okrese Karvina (HBV and HCV prevalence and incidence in IDUs in Karvina District, the Czech Republic)","volume":"2","author":"V Mravcik","year":"2002","journal-title":"Adiktologie"},{"key":"ref62","unstructured":"Mravc\u00edk V, Petro\u0161ov\u00e1 B, Z\u00e1bransk\u00fd T, Reh\u00e1k V, Coufalov\u00e1 M (2009) V\u00fdskyt VHC U I Njekcn\u00edch U\u017eivatelu Drog. Edisko Pro Drogy A Drogove Z\u00e1vislosti 1\u201380."},{"key":"ref63","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1017\/S095026880400247X","article-title":"Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France","volume":"132","author":"D Lucidarme","year":"2004","journal-title":"Epidemiol Infect"},{"key":"ref64","first-page":"1S15","article-title":"[Incidence and risk factors of HCV infection in a cohort of intravenous drug users in the North and East of France]","volume":"1","author":"A Bruandet","year":"2006","journal-title":"Rev Epidemiol Sante Publique 54 Spec No"},{"key":"ref65","unstructured":"Partanen A, Malin K, <etal>et al<\/etal>. (2006) A-klinikkas\u00e4\u00e4ti\u00f6n raportiisarja. 52."},{"key":"ref66","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/jech.57.4.310","article-title":"Retrospective cohort study examining incidence of HIV and hepatitis C infection among injecting drug users in Dublin","volume":"57","author":"BP Smyth","year":"2003","journal-title":"J Epidemiol Community Health"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/BF03169123","article-title":"Bloodborne virus infections among drug users in Ireland: a retrospective cross-sectional survey of screening, prevalence, incidence and hepatitis B immunisation uptake","volume":"174","author":"L Grogan","year":"2005","journal-title":"Ir J Med Sci"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.drugpo.2012.02.002","article-title":"HCV seroconversion among never-injecting heroin users at baseline: no predictors identified other than starting injection","volume":"23","author":"MJ Bravo","year":"2012","journal-title":"Int J Drug Policy"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1365-2893.2010.01400.x","article-title":"Minimal transmission of HIV despite persistently high transmission of hepatitis C virus in a Swedish needle exchange program","volume":"18","author":"MA Blome","year":"2011","journal-title":"J Viral Hepat"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/00365540050165875","article-title":"Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe\/needle exchange program","volume":"32","author":"AS Mansson","year":"2000","journal-title":"Scand J Infect Dis"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/j.1360-0443.2007.01912.x","article-title":"Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users","volume":"102","author":"C van den Berg","year":"2007","journal-title":"Addiction"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10654-006-9089-7","article-title":"Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users","volume":"22","author":"CH van den Berg","year":"2007","journal-title":"Eur J Epidemiol"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.drugpo.2012.07.006","article-title":"Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland","volume":"23","author":"EJ Allen","year":"2012","journal-title":"Int J Drug Policy"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1111\/j.1360-0443.2011.03515.x","article-title":"The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence","volume":"106","author":"KM Turner","year":"2011","journal-title":"Addiction"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1053\/jinf.2001.0908","article-title":"A method to detect the incidence of hepatitis C infection among injecting drug users in Glasgow 1993\u201398","volume":"43","author":"KM Roy","year":"2001","journal-title":"J Infect"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Roy KM, Hutchinson SJ, Wadd S, Taylor A, Cameron SO, et al. (2007) Hepatitis C virus infection among injecting drug users in Scotland: a review of prevalence and incidence data and the methods used to generate them. Epidemiol Infect 135: 433\u2013442. S0950268806007035 [pii]; 10.1017\/S0950268806007035 [doi].","DOI":"10.1017\/S0950268806007035"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1477-7517-5-25","article-title":"The effectiveness of behavioural interventions in the primary prevention of hepatitis C amongst injecting drug users: a randomised controlled trial and lessons learned","volume":"5","author":"M Abou-Saleh","year":"2008","journal-title":"Harm Reduct J"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/j.1365-2893.2008.01009.x","article-title":"Diagnosis of acute hepatitis C virus infection and estimated incidence in low- and high-risk English populations","volume":"15","author":"LJ Brant","year":"2008","journal-title":"J Viral Hepat"},{"key":"ref79","unstructured":"Health Protection Agency, Health Protection Scotland, Public Health Wales, Public Health Agency Northern Ireland (2012) Hepatitis C in the UK, 2012 Report."},{"key":"ref80","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1017\/S095026880900212X","article-title":"Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size","volume":"137","author":"N Craine","year":"2009","journal-title":"Epidemiol Infect"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1365-2893.2010.01297.x","article-title":"Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots","volume":"18","author":"VD Hope","year":"2011","journal-title":"J Viral Hepat"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Balogun MA, Murphy N, Nunn S, Grant A, Andrews NJ, et al. (2009) Prevalence and incidence of hepatitis C in injecting drug users attending genitourinary medicine clinics. Epidemiol Infect 137: 980\u2013987. S0950268808001660 [pii]; 10.1017\/S0950268808001660 [doi].","DOI":"10.1017\/S0950268808001660"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.drugpo.2012.02.003","article-title":"Examination of the risk of reinfection with hepatitis C among injecting drug users who have been tested in Glasgow","volume":"23","author":"SA McDonald","year":"2012","journal-title":"Int J Drug Policy"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/jmv.20124","article-title":"Failure to diagnose recent hepatitis C virus infections in London injecting drug users","volume":"73","author":"E Aarons","year":"2004","journal-title":"J Med Virol"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Judd A, Hickman M, Jones S, McDonald T, Parry JV, et al. (2005) Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ 330: 24\u201325. bmj.38286.841227.7C [pii]; 10.1136\/bmj.38286.841227.7C [doi].","DOI":"10.1136\/bmj.38286.841227.7C"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1023\/A:1010833917242","article-title":"Prevalence and incidence of bloodborne viral infections among Danish prisoners","volume":"16","author":"PB Christensen","year":"2000","journal-title":"Eur J Epidemiol"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/aje\/kwh061","article-title":"Incidence of hepatitis C virus infection and associated risk factors among Scottish prison inmates: a cohort study","volume":"159","author":"JK Champion","year":"2004","journal-title":"Am J Epidemiol"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Grady BP, Vanhommerig JW, Schinkel J, Weegink CJ, Bruisten SM, et al. (2012) Low incidence of reinfection with the hepatitis C virus following treatment in active drug users in Amsterdam. Eur J Gastroenterol Hepatol . 10.1097\/MEG.0b013e32835702a8 [doi].","DOI":"10.1097\/MEG.0b013e32835702a8"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Backmund M, Meyer K, Edlin BR (2004) Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 39: 1540\u20131543. CID33778 [pii]; 10.1086\/425361 [doi].","DOI":"10.1086\/425361"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000052046","article-title":"Prevalence and distribution of hepatitis C subtypes in patients with opioid dependence","volume":"6","author":"W Gombas","year":"2000","journal-title":"Eur Addict Res"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s10096-005-1376-9","article-title":"Molecular epidemiology of hepatitis C among drug users in Flanders, Belgium: association of genotype with clinical parameters and with sex- and drug-related risk behaviours","volume":"24","author":"C Mathei","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/jmv.21145","article-title":"Distribution of hepatitis C virus genotypes among injecting drug users in contact with treatment centers in Belgium, 2004\u20132005","volume":"80","author":"MI Micalessi","year":"2008","journal-title":"J Med Virol"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/S0168-8278(10)60247-4","article-title":"High viral response in a multidisciplinary network not organized under one roof for antiviral management of chronic hepatitis C viral patients infected after substance use","volume":"52","author":"S Bourgeois","year":"2010","journal-title":"Journal of Hepatology"},{"key":"ref94","unstructured":"Reitox National Focal Point Bulgaria (2009) 2009 National Report (2008 Data) to the EMCDDA. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.emcdda.europa.eu\/attachements.cfm\/att_142615_EN_BG-NR2009.pdf\" xlink:type=\"simple\">http:\/\/www.emcdda.europa.eu\/attachements.cfm\/att_142615_EN_BG-NR2009.pdf<\/ext-link>."},{"key":"ref95","unstructured":"Teoharov P, Pavlov I (2009) Genetic diversity of hepatitis C virus among Bulgarian injecting drug users with hepatitis C. Clinical Microbiology and Infection. Conference: 19<sup>th<\/sup> European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) Helsinki Finland. Conference Start: 20090516 Conference End: 20090519. Conference Publication: (var.pagings). 15 (pp S594), 2009. Date of Publication: May 2009. [Journal: Conference Abstract]. Clinical Microbiology and Infection."},{"key":"ref96","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/jmv.21690","article-title":"Hepatitis C infection among intravenous drug users attending therapy programs in Cyprus","volume":"82","author":"VL Demetriou","year":"2010","journal-title":"J Med Virol"},{"key":"ref97","first-page":"84","article-title":"Current situation and trends in the hepatitis C virus genotype distribution among injecting drug users in the Czech Republic","volume":"58","author":"L Krekulova","year":"2009","journal-title":"Epidemiol Mikrobiol Imunol"},{"key":"ref98","unstructured":"Nechanska B (2013) Udaje v Narodnim registru uzivatelu lekarsky indikovanych substitucnich latek - rok 2012 (Information in the National Register of Medically Indicated Substitution Substances - 2012). Aktualni informace."},{"key":"ref99","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1002\/jmv.21836","article-title":"Decline in hepatitis B infection observed after 11 years of regional vaccination among Danish drug users","volume":"82","author":"BK Mossner","year":"2010","journal-title":"J Med Virol"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"e22476","DOI":"10.1371\/journal.pone.0022476","article-title":"Mortality among patients with cleared hepatitis C virus infection compared to the general population: a Danish nationwide cohort study","volume":"6","author":"LH Omland","year":"2011","journal-title":"PLoS One"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1034\/j.1399-0039.2000.560207.x","article-title":"Study of host- and virus-related factors associated with spontaneous hepatitis C virus clearance","volume":"56","author":"L Alric","year":"2000","journal-title":"Tissue Antigens"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1046\/j.1423-0410.2000.7930138.x","article-title":"Hepatitis C virus: routes of infection and genotypes in a cohort of anti-HCV-positive French blood donors","volume":"79","author":"MH Elghouzzi","year":"2000","journal-title":"Vox Sang"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0399-8320(04)95008-7","article-title":"Management of hepatitis C in active drugs users: experience of an addiction care hepatology unit","volume":"28","author":"M Cournot","year":"2004","journal-title":"Gastroenterol Clin Biol"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0399-8320(07)89415-2","article-title":"Routine practice HCV infection screening with saliva samples: multicentric study in an intravenous drug user population","volume":"31","author":"D Lucidarme","year":"2007","journal-title":"Gastroenterol Clin Biol"},{"key":"ref105","doi-asserted-by":"crossref","unstructured":"Moussalli J, Delaquaize H, Boubilley D, Lhomme JP, Merleau PJ, et al. (2010) Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre. Gastroenterol Res Pract 2010. 10.1155\/2010\/261472 [doi].","DOI":"10.1155\/2010\/261472"},{"key":"ref106","first-page":"11","article-title":"Epidemiology of Chronic Hepatitis C Virus Infection in High Risk Groups","volume":"8","author":"M Christofidou","year":"2008","journal-title":"Hepatitis Monthly"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/14017430601049365","article-title":"Management of hepatitis C among drug users attending general practice in Ireland: baseline data from the Dublin area hepatitis C in general practice initiative","volume":"13","author":"W Cullen","year":"2007","journal-title":"Eur J Gen Pract"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF03168517","article-title":"Hepatitis C viral clearance in an intravenous drug-using cohort in the Dublin area","volume":"174","author":"S Keating","year":"2005","journal-title":"Ir J Med Sci"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1097\/00042737-200111000-00014","article-title":"Multiple viral infections in a group of intravenous drug users: hepatitis B virus exposure is the risk factor","volume":"13","author":"M Santolamazza","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"e27555","DOI":"10.1371\/journal.pone.0027555","article-title":"Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort","volume":"6","author":"CH van den Berg","year":"2011","journal-title":"PLoS One"},{"key":"ref111","first-page":"672","article-title":"Hepatitis C Virus Genotypes in Injecting Drug Users from Romania","volume":"6","author":"C Sultana","year":"2011","journal-title":"Cent Eur J Med"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1080\/00365540903062143","article-title":"Hepatitis C infection among injection drug users in Stockholm Sweden: prevalence and gender","volume":"41","author":"C Lidman","year":"2009","journal-title":"Scand J Infect Dis"},{"key":"ref113","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jhep.2009.05.027","article-title":"Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam","volume":"51","author":"TJ van de Laar","year":"2009","journal-title":"J Hepatol"},{"key":"ref114","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/pubmed\/fdr097","article-title":"Identifying former injecting drug users infected with hepatitis C: an evaluation of a general practice-based case-finding intervention","volume":"34","author":"BL Cullen","year":"2012","journal-title":"J Public Health (Oxf)"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/qjmed\/94.3.153","article-title":"Managing chronic hepatitis C acquired through intravenous drug use","volume":"94","author":"SL Jowett","year":"2001","journal-title":"QJM"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1111\/j.1365-2893.2010.01380.x","article-title":"The influence of hepatitis C and alcohol on liver-related morbidity and mortality in Glasgow\u2019s injecting drug user population","volume":"18","author":"SA McDonald","year":"2011","journal-title":"J Viral Hepat"},{"key":"ref117","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1053\/jhep.2003.50019","article-title":"Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load","volume":"37","author":"H Hofer","year":"2003","journal-title":"Hepatology"},{"key":"ref118","first-page":"70","article-title":"[Infectious diseases in problem drug users hospitalized in the infectious ward of the Motol University Hospital in 2002\u20132005]","volume":"13","author":"A Vitous","year":"2007","journal-title":"Klin Mikrobiol Infekc Lek"},{"key":"ref119","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1086\/507640","article-title":"Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy","volume":"43","author":"T Santantonio","year":"2006","journal-title":"Clin Infect Dis"},{"key":"ref120","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S1386-6532(00)00154-2","article-title":"HCV genotypes and age distribution in patients of Vienna and surrounding areas","volume":"20","author":"AC Haushofer","year":"2001","journal-title":"J Clin Virol"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/jmv.22154","article-title":"Molecular analysis of hepatitis C virus infection in Bulgarian injecting drug users","volume":"83","author":"M Ciccozzi","year":"2011","journal-title":"J Med Virol"},{"key":"ref122","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1086\/323199","article-title":"Genotypic and epidemiologic characteristics of hepatitis C virus infections among recent injection drug user and nonuser populations","volume":"33","author":"L Krekulova","year":"2001","journal-title":"Clin Infect Dis"},{"key":"ref123","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/jmv.20828","article-title":"Genetic characterization of hepatitis C virus strains in Estonia: fluctuations in the predominating subtype with time","volume":"79","author":"T Tallo","year":"2007","journal-title":"J Med Virol"},{"key":"ref124","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1046\/j.1365-2893.2002.00319.x","article-title":"Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users","volume":"9","author":"M Bourliere","year":"2002","journal-title":"J Viral Hepat"},{"key":"ref125","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2893.2005.00605.x","article-title":"Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study","volume":"12","author":"C Payan","year":"2005","journal-title":"J Viral Hepat"},{"key":"ref126","doi-asserted-by":"crossref","unstructured":"Backmund M, Meyer K, Von Zielonka M, Eichenlaub D (2001) Treatment of hepatitis C infection in injection drug users. Hepatology 34: 188\u2013193. S0270-9139(01)99075-5 [pii]; 10.1053\/jhep.2001.25882 [doi].","DOI":"10.1053\/jhep.2001.25882"},{"key":"ref127","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/(SICI)1096-9071(200002)60:2<122::AID-JMV3>3.0.CO;2-#","article-title":"Changes in the epidemiology of hepatitis C infection in Germany: shift in the predominance of hepatitis C subtypes","volume":"60","author":"RS Ross","year":"2000","journal-title":"J Med Virol"},{"key":"ref128","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1128\/JCM.40.5.1866-1868.2002","article-title":"Epidemiological dynamics of hepatitis C virus among 747 German individuals: new subtypes on the advance","volume":"40","author":"M Schroter","year":"2002","journal-title":"J Clin Microbiol"},{"key":"ref129","first-page":"196","article-title":"Treatment of intravenous drug users with chronic hepatitis C: treatment response, compliance and side effects","volume":"11","author":"E Gigi","year":"2007","journal-title":"Hippokratia"},{"key":"ref130","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2893.2005.00649.x","article-title":"Molecular epidemiology of hepatitis C virus (HCV) in Greece: temporal trends in HCV genotype-specific incidence and molecular characterization of genotype 4 isolates","volume":"13","author":"A Katsoulidou","year":"2006","journal-title":"J Viral Hepat"},{"key":"ref131","doi-asserted-by":"crossref","unstructured":"Manolakopoulos S, Deutsch MJ, Anagnostou O, Karatapanis S, Tiniakou E, et al. (2010) Substitution treatment or active intravenous drug use should not be contraindications forantiviral treatment in drug userswith chronic hepatitis C. Liver International 30: November. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/dx.doi.org\/10.1111\/j.1478-3231.2010.02341.x\" xlink:type=\"simple\">http:\/\/dx.doi.org\/10.1111\/j.1478-3231.2010.02341.x<\/ext-link>.","DOI":"10.1111\/j.1478-3231.2010.02341.x"},{"key":"ref132","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1590\/S0004-28032010000300005","article-title":"Should active injecting drug users receive treatment for chronic hepatitis C","volume":"47","author":"V Papadopoulos","year":"2010","journal-title":"Arq Gastroenterol"},{"key":"ref133","first-page":"26","article-title":"Significant epidemiological changes in chronic hepatitis C infection: results of the nationwide HEPNET-GREECE cohort study","volume":"15","author":"M Raptopoulou","year":"2011","journal-title":"Hippokratia"},{"key":"ref134","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2893.2005.00614.x","article-title":"Changes in epidemiological patterns of HCV infection and their impact on liver disease over the last 20 years in Greece","volume":"12","author":"SP Savvas","year":"2005","journal-title":"J Viral Hepat"},{"key":"ref135","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/jmv.10210","article-title":"Changing molecular epidemiology of hepatitis C virus infection in Northeast Italy","volume":"68","author":"G Dal Molin","year":"2002","journal-title":"J Med Virol"},{"key":"ref136","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1046\/j.1365-2893.2000.00198.x","article-title":"Hepatitis C virus genotypes in a non-cirrhotic Italian population with chronic hepatitis C: correlation with clinical, virological and histological parameters. Results of a prospective multicentre study","volume":"7","author":"G Saracco","year":"2000","journal-title":"J Viral Hepat"},{"key":"ref137","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jcv.2009.04.022","article-title":"Changes in the prevalence of hepatitis C virus genotype among Italian injection drug users-relation to period of injection started","volume":"45","author":"S Sereno","year":"2009","journal-title":"J Clin Virol"},{"key":"ref138","first-page":"H17","article-title":"Changes in hepatitis C virus infection routes and genotype distribution in a Lithuanian cohort with chronic hepatitis C. Med Sci Monit","volume":"15","author":"V Liakina","year":"2009"},{"key":"ref139","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jcv.2008.02.001","article-title":"Changing HCV genotypes distribution in Poland\u2014relation to source and time of infection","volume":"42","author":"S Chlabicz","year":"2008","journal-title":"J Clin Virol"},{"key":"ref140","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/jmv.21955","article-title":"Hepatitis C virus subtypes circulating among intravenous drug users in Lisbon, Portugal","volume":"83","author":"RA Calado","year":"2011","journal-title":"J Med Virol"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/jmv.21427","article-title":"Hepatitis C virus genotypes in 1,504 patients in Slovenia, 1993\u20132007","volume":"81","author":"K Seme","year":"2009","journal-title":"J Med Virol"},{"key":"ref142","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.1365-2893.2003.00372.x","article-title":"Influence of age and date of infection on distribution of hepatitis C virus genotypes and fibrosis stage","volume":"10","author":"MA Serra","year":"2003","journal-title":"J Viral Hepat"},{"key":"ref143","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0213-005X(02)72789-4","article-title":"Prevalence of hepatitis C virus genotypes in the area of El Ferrol (La Coruna, Spain)","volume":"20","author":"S Touceda","year":"2002","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"ref144","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/jmv.20486","article-title":"Changes in risk behavior and dynamics of hepatitis C virus infections among young drug users in Amsterdam, the Netherlands","volume":"77","author":"TJ van de Laar","year":"2005","journal-title":"J Med Virol"},{"key":"ref145","first-page":"34","article-title":"Risk factors, clinical features and genotype distribution of diagnosed hepatitis C virus infections: a pilot for a sentinel laboratory-based surveillance","volume":"6","author":"MA Balogun","year":"2003","journal-title":"Commun Dis Public Health"},{"key":"ref146","doi-asserted-by":"crossref","unstructured":"Jack K, Willott S, Manners J, Varnam MA, Thomson BJ (2009) Clinical trial: a primary-care-based model for the delivery of anti-viral treatment to injecting drug users infected with hepatitis C. Aliment Pharmacol Ther 29: 38\u201345. APT3872 [pii]; 10.1111\/j.1365-2036.2008.03872.x [doi].","DOI":"10.1111\/j.1365-2036.2008.03872.x"},{"key":"ref147","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1136\/gut.48.5.707","article-title":"The epidemiology of hepatitis C in a UK health regional population of 5.12 million","volume":"48","author":"AH Mohsen","year":"2001","journal-title":"Gut"},{"key":"ref148","unstructured":"\u00d6big (2013) Gesundheit \u00d6sterreich GmbH\/ \u00d6sterreichisches Bundesinstitut f\u00fcr Gesundheitswesen - G\u00d6G\/\u00d6BIG (unpublished data)."},{"key":"ref149","unstructured":"Mathe\u00ef C (2011) Internal document. Free Clinic: Antwerp."},{"key":"ref150","unstructured":"National Focal Point (2010) Annual report on the state of drug related problems in Bulgaria."},{"key":"ref151","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1086\/650491","article-title":"CCL3L1 copy number is a strong genetic determinant of HIV seropositivity in Caucasian intravenous drug users","volume":"201","author":"K Huik","year":"2010","journal-title":"J Infect Dis"},{"key":"ref152","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/MEG.0b013e3282f479ab","article-title":"Evaluation of the French national plan to promote screening and early management of viral hepatitis C, between 1997 and 2003: a comparative cross-sectional study in Poitou-Charentes region","volume":"20","author":"G Defossez","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref153","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1471-2334-9-113","article-title":"A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design","volume":"9","author":"M Jauffret-Roustide","year":"2009","journal-title":"BMC Infect Dis"},{"key":"ref154","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000085549","article-title":"Risk Factors and predictors of human immunodeficiency virus infection among injection drug users","volume":"11","author":"M Backmund","year":"2005","journal-title":"Eur Addict Res"},{"key":"ref155","first-page":"913","article-title":"Burden of disease and level of patient\u2019s medical care in substitution treatment for opiates","volume":"104","author":"MC Muller","year":"2009","journal-title":"Med Klin"},{"key":"ref156","unstructured":"Zimmermann R (2012) DRUCK-Studie - Drogen und chronische Infektionskrankheiten in Deutschland. Ergebnisse der Pilotierung eines Sero- und Verhaltenssurveys bei i.v. Drogengebrauchern. Epidem Bull 33."},{"key":"ref157","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1017\/S0950268803008318","article-title":"Prevalence and risk factors of HIV, hepatitis B and hepatitis C in a forensic population of rapists and child molesters","volume":"130","author":"O Giotakos","year":"2003","journal-title":"Epidemiol Infect"},{"key":"ref158","unstructured":"Focal Point (2009) Greek REITOX Focal Point (EKTEPN), University Mental Health Research Institute (UMHRI) (unpublished data)."},{"key":"ref159","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/eurpub\/ckp009","article-title":"Vulnerability to drug-related infections and co-infections among injecting drug users in Budapest, Hungary","volume":"19","author":"VA Gyarmathy","year":"2009","journal-title":"Eur J Public Health"},{"key":"ref160","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s11524-011-9626-x","article-title":"Prevalence and correlates of HCV, HVB, and HIV infection among prison inmates and staff, Hungary","volume":"89","author":"B Treso","year":"2012","journal-title":"J Urban Health"},{"key":"ref161","first-page":"59","article-title":"Continued high prevalence of HIV, HBV and HCV among injecting and noninjecting drug users in Italy","volume":"46","author":"L Camoni","year":"2010","journal-title":"Ann Ist Super Sanita"},{"key":"ref162","first-page":"101","article-title":"Risk factors for HBV\/HIV\/HCV in drug addicts: a survey of attendees of a department of pathological dependence","volume":"51","author":"C Napoli","year":"2010","journal-title":"J Prev Med Hyg"},{"key":"ref163","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1086\/375566","article-title":"Factors associated with hepatitis C virus infection in injection and noninjection drug users in Italy","volume":"37","author":"G Quaglio","year":"2003","journal-title":"Clin Infect Dis"},{"key":"ref164","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jmv.20375","article-title":"Correlates of HIV, HBV, and HCV infections in a prison inmate population: results from a multicentre study in Italy","volume":"76","author":"S Babudieri","year":"2005","journal-title":"J Med Virol"},{"key":"ref165","unstructured":"Trapencieris M, Snikere S, Petersons A, Kaupe R (2013) Drug use patterns and trends in Latvia. Drug users cohort study 6th phase results (Narkotiku lietosanas paradumi un tendences Latvija. Narkotiku lietotaju kohortas petijuma 6. posma rezultati)."},{"key":"ref166","unstructured":"National Institute of Health Development (2009) Prevalence of HIV and other Infections and Risk Behaviour Among Injecting Drug Users In Latvia, Lithuania And Estonia in 2007 Study report, 2009. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/balthiv.com\/download-doc.php?file=ENCAP_ENG.pdf\" xlink:type=\"simple\">http:\/\/balthiv.com\/download-doc.php?file=ENCAP_ENG.pdf<\/ext-link>."},{"key":"ref167","unstructured":"Karnite A, Uusk\u00fcla A, Luizov A, Rusev A, Talu A, et al. (2013) Assessment on HIV and TB knowledge and the barriers related to access to care among vulnerable groups. Report on a cross-sectional study among injecting drug users. (Zina-\u0161anas par HIV un tuberkulozi un \u0161k, e-r\u0161l, i apru-pes san, em\u0161anai socia-la-s atstumti-bas riska grupa-s. Injice-jamo narkotiku lietota-ju vidu- veikta \u0161k, e-rsgriezuma pe-ti-juma rezulta-ti) (in press)."},{"key":"ref168","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/1471-2458-11-351","article-title":"A hepatitis A, B, C and HIV prevalence and risk factor study in ever injecting and non-injecting drug users in Luxembourg associated with HAV and HBV immunisations","volume":"11","author":"N Removille","year":"2011","journal-title":"BMC Public Health"},{"key":"ref169","unstructured":"Bielak A, Zielinski A (2002) Wystepowanie chorob zakaznych (wzw typu B i C, HIV) wsrod narkomanow przyjmujacych dozylne srodki odurzajace. [Infectious diseases (HBV, HCV and HIV) among injecting drug users.] (unpublished data)."},{"key":"ref170","unstructured":"Rosinska M, Zielinski A (2004) Estimating the prevalence of infectious diseases (hepatitis C and B, HIV) among drug users taking drugs by injection in cities with varying degrees of implementation of harm reduction programs (Oszacowanie wystepowania chorob zakaznych (wirusowe zapalenie watroby typu C i B, HIV) wsrod narkomanow przyjmujacych srodki odurzajace w iniekcji w miastach o roznym stopniu realizacji programow redukcji szkod)."},{"key":"ref171","unstructured":"Rosinska M (2005) Estimating the prevalence of infectious diseases (hepatitis C and B, HIV) among drug users taking drugs by injection with a special emphasis on migration between countries (Oszacowanie wystepowania chorob zakaznych (wirusowe zapalenie watroby typu C i B, HIV) wsrod narkomanow przyjmujacych srodki odurzajace w iniekcji ze szczegolnym uwzglednieniem migracji pomiedzy krajami)."},{"key":"ref172","unstructured":"Rosinska M (2009) Estimating the prevalence of infectious diseases (hepatitis C and B, HIV) among people who injected drugs in Gdansk and Krakow (Oszacowanie wystepowania chorob zakaznych (wirusowe zapalenie watroby typu C i B, HIV) wsrod osob przyjmujacych srodki odurzajace we wstrzyknieciach w Gdansku i w Krakowie)."},{"key":"ref173","doi-asserted-by":"crossref","first-page":"116","DOI":"10.21101\/cejph.a3477","article-title":"A survey of HIV and HCV among female prison inmates in Portugal","volume":"16","author":"H Barros","year":"2008","journal-title":"Cent Eur J Public Health"},{"key":"ref174","unstructured":"Institute of Public Health (2008) Report on the Drug Situation 2008 of the Republic of Slovenia. 68\u201369."},{"key":"ref175","first-page":"53","article-title":"[Predictive markers of HIV and HCV infection and co-infection among inmates in a Spanish prison]","volume":"23","author":"P Saiz de la Hoya","year":"2005","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"ref176","first-page":"142","article-title":"[Hepatitis C virus infection in a first level rural hospital: descriptive study in the decade 1991\u20131999]","volume":"21","author":"FF Rodriguez-Vidigal","year":"2003","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"ref177","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/01.aids.0000196164.71388.3b","article-title":"Impact of hepatitis C infection on long-term mortality of injecting drug users from 1990 to 2002: differences before and after HAART","volume":"20","author":"B Lumbreras","year":"2006","journal-title":"AIDS"},{"key":"ref178","first-page":"570","article-title":"Rate of infection by blood-borne viruses in active heroin users in 3 Spanish cities","volume":"122","author":"S Bassani","year":"2004","journal-title":"Med Clin (Barc )"},{"key":"ref179","first-page":"504","article-title":"Profile of drug users admitted to a hospital","volume":"20","author":"CT de los Cobos","year":"2003","journal-title":"An Med Interna"},{"key":"ref180","doi-asserted-by":"crossref","unstructured":"Folch C, Casabona J, Espelt A, Majo X, Merono M, et al. (2013) Gender differences in HIV risk behaviours among intravenous drug users in Catalonia, Spain. Gac Sanit.","DOI":"10.1016\/j.gaceta.2013.02.006"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1023\/A:1014560431726","article-title":"Measures to reduce HIV infection have not been successful to reduce the prevalence of HCV in intravenous drug users","volume":"17","author":"I Hernandez-Aguado","year":"2001","journal-title":"Eur J Epidemiol"},{"key":"ref182","first-page":"236","article-title":"[Prevalence of human immunodeficiency virus and hepatitis C virus, and associated factors among injecting drug users in Catalonia]","volume":"28","author":"S Huntington","year":"2010","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"ref183","unstructured":"Folch C, Casabona J, Brugal MT, Maj\u00f3 X, Mero\u00f1o M, et al. (2009) Prevalencia de VIH, VHC y de otras ITS en usuarios de droga por v\u00eda parenteral reclutados en centros de reducci\u00f3n de da\u00f1os [Prevalence of HIV, HCV and other STIs among IDUs recruited from harm reduction centres]."},{"key":"ref184","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2174\/157016211796320298","article-title":"Estimated liver fibrosis and its impact on all-cause mortality of HCV-monoinfected and HCV\/HIV-coinfected drug users","volume":"9","author":"A Sanvisens","year":"2011","journal-title":"Curr HIV Res"},{"key":"ref185","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2105\/AJPH.91.1.38","article-title":"Prevalence of hepatitis C among injection drug users in England and Wales: is harm reduction working","volume":"91","author":"VD Hope","year":"2001","journal-title":"Am J Public Health"},{"key":"ref186","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/sextrans-2011-050450","article-title":"Male IDUs who have sex with men in England, Wales and Northern Ireland: are they at greater risk of bloodborne virus infection and harm than those who only have sex with women","volume":"88","author":"A Marongiu","year":"2012","journal-title":"Sex Transm Infect"},{"key":"ref187","unstructured":"Health Protection Scotland (2008) The Needle Exchange Surveillance Initiative (NESI): Prevalence of HCV, HIV and injecting risk behaviours among injecting drug users attending needle exchanges in Scotland, 2007."},{"key":"ref188","doi-asserted-by":"crossref","unstructured":"Wilkinson M, Crawford V, Tippet A, Jolly F, Turton J, et al. (2009) Community-based treatment for chronic hepatitis C in drug users: High rates of compliance with therapy despite ongoing drug use. Alimentary Pharmacology and Therapeutics 29: January. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/dx.doi.org\/10.1111\/j.1365-2036.2008.03834.x\" xlink:type=\"simple\">http:\/\/dx.doi.org\/10.1111\/j.1365-2036.2008.03834.x<\/ext-link>.","DOI":"10.1111\/j.1365-2036.2008.03834.x"},{"key":"ref189","unstructured":"HPA HPS, National Public Health Service for Wales, CDSC Northern Ireland, CRDHB (2009) Shooting Up: Infections among injecting drug users in the United Kingdom 2008."},{"key":"ref190","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/1471-2334-12-178","article-title":"Hepatitis C prevalence in Denmark -an estimate based on multiple national registers","volume":"12","author":"PB Christensen","year":"2012","journal-title":"BMC Infect Dis"},{"key":"ref191","doi-asserted-by":"crossref","unstructured":"Jauffret-Roustide M, Emmanuelli J, Quaglia M, Barin F, Arduin P, et al. (2006) Impact of a harm-reduction policy on HIV and hepatitis C virus transmission among drug users: recent French data\u2014the ANRS-Coquelicot Study. Subst Use Misuse 41: 1603\u20131621. W461677756681022 [pii]; 10.1080\/10826080600847951 [doi].","DOI":"10.1080\/10826080600847951"},{"key":"ref192","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2893.2010.01415.x","article-title":"Hepatitis C infection among recent initiates to injecting in England 2000\u20132008: Is a national hepatitis C action plan making a difference","volume":"19","author":"V Hope","year":"2012","journal-title":"J Viral Hepat"},{"key":"ref193","unstructured":"Health Protection Agency, Health Protection Scotland, Public Health Wales, Public Health Agency Northern Ireland (2012) Unlinked Anonymous Monitoring Survey of People Who Inject Drugs in contact with specialist services: data tables update July 2012. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.hpa.org.uk\/webc\/HPAwebFile\/HPAweb_C\/1317135226434\" xlink:type=\"simple\">http:\/\/www.hpa.org.uk\/webc\/HPAwebFile\/HPAweb_C\/1317135226434<\/ext-link>."},{"key":"ref194","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1017\/S0950268809990616","article-title":"Diagnosis of hepatitis C virus infection in Scotland\u2019s injecting drug user population","volume":"138","author":"SA McDonald","year":"2010","journal-title":"Epidemiol Infect"},{"key":"ref195","doi-asserted-by":"crossref","unstructured":"McDonald SA, Hutchinson SJ, Palmateer NE, Allen E, Cameron SO, et al. (2013) Decrease in health-related quality of life associated with awareness of hepatitis C virus infection among people who inject drugs in Scotland. J Hepatol 58: 460\u2013466. S0168-8278(12)00836-7 [pii]; 10.1016\/j.jhep.2012.11.004 [doi].","DOI":"10.1016\/j.jhep.2012.11.004"},{"key":"ref196","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S0399-8320(07)78338-0","article-title":"HEPACOM: multicenter, observational prospective study of outcome and monitoring of HCV positive antiviral-na\u00efve patients managed in the French health care system","volume":"31","author":"H Agostini","year":"2007","journal-title":"Gastroenterologie Clinique et Biologique"},{"key":"ref197","unstructured":"Grando-Lemaire V, Goisset P, Sorge F, Trinchet JC, Castera L, et al. (2002) Hepatitis C virus screening in drug users in an addiction out-patient unit. Gastroenterol Clin Biol 26: 1091\u20131096. MDOI-GCB-12-2002-26-12-0399-8320-101019-ART5 [pii]."},{"key":"ref198","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.drugalcdep.2009.04.002","article-title":"Access to care of patients with chronic hepatitis C virus infection in a university hospital: Is opioid dependence a limiting condition","volume":"104","author":"V Perut","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"ref199","doi-asserted-by":"crossref","unstructured":"Schulte B, Schutt S, Brack J, Isernhagen K, Deibler P, et al. (2010) Successful treatment of chronic hepatitis C virus infection in severely opioid-dependent patients under heroin maintenance. Drug Alcohol Depend 109: 248\u2013251. S0376-8716(10)00036-0 [pii]; 10.1016\/j.drugalcdep.2010.01.009 [doi].","DOI":"10.1016\/j.drugalcdep.2010.01.009"},{"key":"ref200","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1413-8670(11)70164-7","article-title":"Difficulties with interferon treatment in former intravenous drug users","volume":"15","author":"G Gazdag","year":"2011","journal-title":"Braz J Infect Dis"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"223","DOI":"10.21101\/cejph.a3747","article-title":"Referral of intravenous drug users for antiviral treatment: effectiveness of hepatitis C case-finding programmes","volume":"20","author":"G Gazdag","year":"2012","journal-title":"Cent Eur J Public Health"},{"key":"ref202","first-page":"73","article-title":"Experience of hepatitis C among current or former heroin users attending general practice","volume":"98","author":"W Cullen","year":"2005","journal-title":"Ir Med J"},{"key":"ref203","doi-asserted-by":"crossref","unstructured":"Guadagnino V, Trotta MP, Montesano F, Babudieri S, Caroleo B, et al. (2007) Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxification programmes. Addiction 102: 423\u2013431. ADD1698 [pii]; 10.1111\/j.1360-0443.2006.01698.x [doi].","DOI":"10.1111\/j.1360-0443.2006.01698.x"},{"key":"ref204","first-page":"2001","article-title":"Chronic hepatitis (HCV) among intravenous drug users (IDU); reasons for not initiating the antiviral treatment. [Spanish]","volume":"13","author":"J Crespo","year":"2001","journal-title":"Adicciones"},{"key":"ref205","doi-asserted-by":"crossref","unstructured":"Croes E, Veen van de C (2012) Hepatitis C in de verslavingszorg. De effectiviteit van de hepatitis C informatiecampagne.","DOI":"10.1007\/s12501-013-0016-1"},{"key":"ref206","unstructured":"Van Veen M (2009) Briefrapport Infectieziektebestrijding in de verslavingszorg in Nederland."},{"key":"ref207","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2893.2009.01175.x","article-title":"Mortality in HIV-infected injection drug users with active vs cleared hepatitis C virus-infection: a population-based cohort study","volume":"17","author":"LH Omland","year":"2010","journal-title":"J Viral Hepat"},{"key":"ref208","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2012.06.010","article-title":"All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection","volume":"57","author":"V Hernando","year":"2012","journal-title":"J Hepatol"},{"key":"ref209","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.cgh.2011.05.012","article-title":"No impact of hepatitis C virus infection on mortality among drug users during the first decade after seroconversion","volume":"9","author":"B Grady","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref210","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1360-0443.2011.03654.x","article-title":"The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam","volume":"107","author":"A Matser","year":"2012","journal-title":"Addiction"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/hep.20836","article-title":"Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland","volume":"42","author":"SJ Hutchinson","year":"2005","journal-title":"Hepatology"},{"key":"ref212","doi-asserted-by":"crossref","unstructured":"Rondy M, Wiessing L, Hutchinson SJ, Mathei C, Mathis F, et al. (2013) Hepatitis C prevalence in injecting drug users in Europe, 1990\u20132007: impact of study recruitment setting. Epidemiol Infect 141: 563\u2013572. S0950268812000921 [pii]; 10.1017\/S0950268812000921 [doi].","DOI":"10.1017\/S0950268812000921"},{"key":"ref213","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/hep.26926","article-title":"Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection","volume":"59","author":"S Lattimore","year":"2014","journal-title":"Hepatology"},{"key":"ref214","doi-asserted-by":"crossref","unstructured":"Barreiro P, Fernandez-Montero JV, de Mendoza C, Labarga P, Soriano V (2014) Towards hepatitis C eradication from the HIV-infected population. Antiviral Res 105: 1\u20137. S0166-3542(14)00038-2 [pii]; 10.1016\/j.antiviral.2014.02.004 [doi].","DOI":"10.1016\/j.antiviral.2014.02.004"},{"key":"ref215","unstructured":"Janssen-Cilag International NV (2014) OLYSIO (simeprevir) receives marketing authorisation in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.jnj.com\/news\/all\/OLYSIO-simeprevir-receives-marketing-authorisation-in-the-European-Union-for-the-treatment-of-adults-with-hepatitis-C-genotype-1-and-4-infection\" xlink:type=\"simple\">https:\/\/www.jnj.com\/news\/all\/OLYSIO-simeprevir-receives-marketing-authorisation-in-the-European-Union-for-the-treatment-of-adults-with-hepatitis-C-genotype-1-and-4-infection<\/ext-link>."},{"key":"ref216","unstructured":"Hill A, Khoo S, Simmons B, Ford N (2013) What is the minimum cost per person to cure HCV?"},{"key":"ref217","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.meegid.2004.08.001","article-title":"The hepatitis C virus epidemic among injecting drug users","volume":"5","author":"OG Pybus","year":"2005","journal-title":"Infect Genet Evol"},{"key":"ref218","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1086\/380821","article-title":"Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis","volume":"189","author":"L van Asten","year":"2004","journal-title":"J Infect Dis"},{"key":"ref219","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1128\/JCM.01146-09","article-title":"Emergence of hepatitis C virus genotype 4: phylogenetic analysis reveals three distinct epidemiological profiles","volume":"47","author":"J de Bruijne","year":"2009","journal-title":"J Clin Microbiol"},{"key":"ref220","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/jmv.21896","article-title":"Molecular and epidemiological profiles of hepatitis C virus genotype 4 in Denmark","volume":"82","author":"MB Eriksen","year":"2010","journal-title":"J Med Virol"},{"key":"ref221","doi-asserted-by":"crossref","unstructured":"Vickerman P, Grebely J, Dore GJ, Sacks-Davis R, Page K, <etal>et al<\/etal>. (2012) The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design. J Infect Dis 205: 1342\u20131350. jis213 [pii]; 10.1093\/infdis\/jis213 [doi].","DOI":"10.1093\/infdis\/jis213"},{"key":"ref222","doi-asserted-by":"crossref","unstructured":"Kielland KB, Skaug K, Amundsen EJ, Dalgard O (2013) All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study. J Hepatol 58: 31\u201337. S0168-8278(12)00687-3 [pii]; 10.1016\/j.jhep.2012.08.024 [doi].","DOI":"10.1016\/j.jhep.2012.08.024"},{"key":"ref223","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1111\/jvh.12245","article-title":"Lower life expectancy among people with an HCV notification: a population-based linkage study","volume":"21","author":"M Alavi","year":"2014","journal-title":"J Viral Hepat"},{"key":"ref224","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2471\/BLT.12.108282","article-title":"Mortality among people who inject drugs: a systematic review and meta-analysis","volume":"91","author":"BM Mathers","year":"2013","journal-title":"Bull World Health Organ"},{"key":"ref225","doi-asserted-by":"crossref","unstructured":"Hope VD, Eramova I, Capurro D, Donoghoe MC (2014) Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect 142: 270\u2013286. S0950268813000940 [pii]; 10.1017\/S0950268813000940 [doi].","DOI":"10.1017\/S0950268813000940"},{"key":"ref226","doi-asserted-by":"crossref","unstructured":"Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, et al. (2008) Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 372: 1733\u20131745. S0140-6736(08)61311-2 [pii]; 10.1016\/S0140-6736(08)61311-2 [doi].","DOI":"10.1016\/S0140-6736(08)61311-2"},{"key":"ref227","doi-asserted-by":"crossref","unstructured":"Wiessing L, van de Laar MJ, Donoghoe MC, Guarita B, Klempova D, et al. (2008) HIV among injecting drug users in Europe: increasing trends in the East. Euro Surveill 13.","DOI":"10.2807\/ese.13.50.19067-en"},{"key":"ref228","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/jurban\/79.4.579","article-title":"Case-reporting of acute hepatitis B and C among injection drug users","volume":"79","author":"H Hagan","year":"2002","journal-title":"J Urban Health"},{"key":"ref229","unstructured":"Hansen N, Cowan S, Christensen PB, Weis N (2008) Reporting chronic hepatitis B and C in Denmark. Ugeskr Laeger 170: 1567\u20131570. VP52123 [pii]."},{"key":"ref230","doi-asserted-by":"crossref","unstructured":"Sutton AJ, Hope VD, Mathei C, Mravcik V, Sebakova H, et al. (2008) A comparison between the force of infection estimates for blood-borne viruses in injecting drug user populations across the European Union: a modelling study. J Viral Hepat 15: 809\u2013816. JVH1041 [pii]; 10.1111\/j.1365-2893.2008.01041.x [doi].","DOI":"10.1111\/j.1365-2893.2008.01041.x"},{"key":"ref231","unstructured":"ECDC (2013) Hepatitis B and C surveillance in Europe 2006\u20132011. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ecdc.europa.eu\/en\/publications\/Publications\/Hepatitis-B-C-surveillance-report-2006-2011.pdf\" xlink:type=\"simple\">http:\/\/www.ecdc.europa.eu\/en\/publications\/Publications\/Hepatitis-B-C-surveillance-report-2006-2011.pdf<\/ext-link>."},{"key":"ref232","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0140-6736(10)60232-2","article-title":"HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage","volume":"375","author":"BM Mathers","year":"2010","journal-title":"Lancet"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0103345","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T23:39:24Z","timestamp":1746315564000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0103345"}},"subtitle":[],"editor":[{"given":"Yury E.","family":"Khudyakov","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2014,7,28]]},"references-count":232,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2014,7,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0103345","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,28]]}}}